CRIS · XBRL financial data

Curis financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CRIS's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23†Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Revenue from contracts with customers	3	3*	2	3	3	3*	2	3	3	1*	0	0
General and administrative	5	5*	5	5	4	3*	4	4	4	3*	5	3
Operating income (loss)	(12)	(12)*	(12)	(13)	(11)	(9)*	(10)	(8)	(7)	20*	(12)	(10)
Interest income	1	1*	1	1	0	0*	0	0	0	0*	0	0
Income tax expense (benefit)	—	—	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(12)	(12)*	(12)	(12)	(10)	(10)*	(11)	(9)	(8)	19*	(24)	(9)
Earnings per share, basic‡ USD per share	(42.60)	—	(2.05)	(2.03)	(1.70)	(1.25)*	(1.25)	(0.68)	(0.49)	—	(1.25)	(4.02)
Earnings per share, diluted‡ USD per share	(42.60)	—	(2.05)	(2.03)	(1.70)	(1.25)*	(1.25)	(0.68)	(0.49)	—	(1.25)	(4.02)
Weighted average shares, basic‡ millions of shares	0	—	6	6	6	8*	8	13	16	16*	19	2
Weighted average shares, diluted‡ millions of shares	0	—	6	6	6	8*	8	13	16	16*	19	2

† Share count changed about 20x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/19 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (CRIS's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23†Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Cash and cash equivalents	24	27	30	10	21	20	20	10	9	5	15	5
Marketable securities	44	30	11	18	0	0	—	—	—	—	—	—
Accounts receivable	3	3	2	3	3	3	2	3	3	0	—	—
Prepaid and other current assets	2	2	3	4	3	3	2	2	2	2	2	1
Total current assets	73	61	46	35	27	26	25	14	14	7	17	7
Property and equipment, net	0	0	0	0	0	0	0	0	0	0	0	0
Right-of-use asset	3	3	3	4	3	3	3	3	2	2	2	1
Goodwill	9	9	9	9	9	9	9	9	9	9	9	9
Total assets	90	77	62	50	42	41	39	29	28	20	30	19
Accounts payable	5	3	4	2	4	3	5	4	4	6	7	5
Accrued liabilities	7	9	6	7	8	7	6	7	7	7	7	7
Current portion of long-term debt	—	9	—	—	—	8	7	7	7	0	—	—
Total current liabilities	14	14	11	19	22	19	20	19	20	14	15	14
Lease liability, non-current	2	1	1	2	2	2	1	1	1	0	0	0
Total liabilities	60	58	53	51	51	47	46	43	42	15	17	14
Accumulated deficit	(1,185)	(1,196)	(1,208)	(1,220)	(1,230)	(1,240)	(1,250)	(1,259)	(1,267)	(1,247)	(1,272)	(1,280)
Total stockholders' equity	30	20	9	(1)	(9)	(6)	(7)	(14)	(15)	5	13	5
Total liabilities and equity	90	77	62	50	42	41	39	29	28	20	30	19
Common shares outstanding (cover page)‡ millions of shares	0	6	6	6	8	8	10	12	13	40	39	2

† Share count changed about 20x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/19 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (CRIS's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23†Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Net income (loss)	(12)	(12)*	(12)	(12)	(10)	(10)*	(11)	(9)	(8)	19*	(24)	(9)
Stock-based compensation	2*	2*	2	2*	1*	1*	1	1*	1*	1*	1	1*
Net cash from operating activities	(8)*	(10)*	(13)	(11)*	(6)*	(9)*	(7)	(8)*	(6)*	(6)*	(9)	(10)*
Purchases of property and equipment	0*	0*	—	—	—	—	—	—	—	—	—	—
Net cash from investing activities	0*	15*	19	(7)*	18*	(0)*	0	0*	0*	3*	0	0*
Proceeds from issuing common stock	(0)*	14*	0	0*	1*	11*	10	(1)*	6*	(0)*	19	(0)*
Net cash from financing activities	13*	(2)*	(2)	(1)*	(2)*	9*	8	(2)*	4*	(0)*	19	(0)*
Net change in cash	5*	2*	3	(20)*	11*	(1)*	0	(10)*	(1)*	(4)*	10	(10)*

† Share count changed about 20x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/19 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Curis	5.1	0	(9.6)*	2.1M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Kala Bio	0.2	not reported	(1.5)*	19.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Lexaria Bioscience	3.5	0	(1.6)*	24.8M	2.2 quarters	Q3 FY26 10-QMay 31, 2026
Pulmatrix	2.2	not reported	(1.1)*	3.7M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Dyadic International	1.4	1	(1.8)*	36.4M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Scynexis	10	0.2	(15)*	9.9M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Aytu Biopharma	26	16*	4.4*	10.9M	—	Q4 FY26 10-KJun 30, 2026
Palatin Technologies	7.5	0.3*	(2.7)*	1.8M	2.8 quarters	Q4 FY26 10-KJun 30, 2026
Tenax Therapeutics	118	0*	(14)*	37.4M	8.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.